EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients

Fabian M Troschel iD, Benjamin O Troschel, Maren Kloss, Johanna Jost iD, Niklas B Pepper iD, Amelie S Völk-Troschel iD, Rainer G Wiewrodt iD, Walter Stummer iD, Dorothee Wiewrodt iD, Hans Theodor Eich

Strahlentherapie und Onkologie · 2024

DOI: 10.1007/s00066-024-02225-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, 2024. Verfasst von Fabian M Troschel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. fabian.troschel@uni-muenster.de. Hauptthemen laut MEDLINE: Sarcopenia, Glioblastoma, Chemoradiotherapy, Brain Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Sarcopenia may complicate treatment in cancer patients. Herein, we assessed whether sarcopenia measurements derived from radiation planning computed tomography (CT) were associated with complications and tumor progression during radiochemotherapy for glioblastoma.

Methods

Consecutive patients undergoing radiotherapy planning for glioblastoma between 2010 and 2021 were analyzed. Retrocervical muscle cross-sectional area (CSA) was measured via threshold-based semi-automated radiation planning CT analysis. Patients in the lowest sex-specific quartile of muscle measurements were defined as sarcopenic. We abstracted treatment characteristics and tumor progression from the medical records and performed uni- and multivariable time-to-event analyses.

Results

We included 363 patients in our cohort (41.6% female, median age 63 years, median time to progression 7.7 months). Sarcopenic patients were less likely to receive chemotherapy ( p < 0.001) and more likely to be treated with hypofractionated radiotherapy ( p = 0.005). Despite abbreviated treatment, they more often discontinued radiotherapy ( p = 0.023) and were more frequently prescribed corticosteroids ( p = 0.014). After treatment, they were more often transferred to inpatient palliative care treatment ( p = 0.035). Finally, progression-free survival was substantially shorter in sarcopenic patients in univariable (median 5.1 vs. 8.4 months, p < 0.001) and multivariable modeling (hazard ratio 0.61 [confidence interval 0.46–0.81], p = 0.001).

Conclusion

Sarcopenia is a strong risk factor for treatment discontinuation and reduced progression-free survival in glioblastoma patients. We propose that sarcopenic patients should receive intensified supportive care during radiotherapy and during follow-up as well as expedited access to palliative care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaGlioblastomaChemoradiotherapyBrain NeoplasmsProgression-Free SurvivalHumansFemaleMaleMiddle AgedAgedTomography, X-Ray ComputedDisease ProgressionRadiotherapy Planning, Computer-AssistedRadiation Dose HypofractionationRetrospective StudiesWithholding Treatment

Stichwörter der Autor:innen

Body compositionComputed tomographyFrailtyPalliative carePrognostic biomarkerRadiation therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. fabian.troschel@uni-muenster.de.
  • Department of Radiation Oncology, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  • Department of Neurosurgery, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  • Department of Medicine II, Klinikum Wolfsburg, Sauerbruchstraße 7, 38440, Wolfsburg, Germany.
  • Pulmonary Research Division, Münster University, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
  • Department of Pulmonary Medicine, Mathias Foundation, Hospitals Rheine and Ibbenbüren, Frankenburgsstraße 31, 48431, Rheine, Germany.

ORCID-Profile: Fabian M Troschel, Johanna Jost, Niklas B Pepper, Amelie S Völk-Troschel, Rainer G Wiewrodt, Walter Stummer, Dorothee Wiewrodt

Förderung

  • Universitätsklinikum Münster

Zitieren

APA

Troschel, F. M., Troschel, B. O., Kloss, M., Jost, J., Pepper, N. B., Völk-Troschel, A. S., Wiewrodt, R. G., Stummer, W., Wiewrodt, D., & Eich, H. T. (2024). Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-024-02225-7

Vancouver

Troschel FM, Troschel BO, Kloss M, Jost J, Pepper NB, Völk-Troschel AS, et al. Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients. Strahlentherapie und Onkologie. 2024. doi:10.1007/s00066-024-02225-7

BibTeX
@article{Troschel2024,
  author = {Troschel, Fabian M and Troschel, Benjamin O and Kloss, Maren and Jost, Johanna and Pepper, Niklas B and Völk-Troschel, Amelie S and Wiewrodt, Rainer G and Stummer, Walter and Wiewrodt, Dorothee and Eich, Hans Theodor},
  title = {Sarcopenia is associated with chemoradiotherapy discontinuation and reduced progression-free survival in glioblastoma patients},
  journal = {Strahlentherapie und Onkologie},
  year = {2024},
  doi = {10.1007/s00066-024-02225-7}
}
Kostenlos starten →